Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Buruli Ulcer | 1 | 2018 | 17 | 0.74 | Why? |
| Hyphae | 1 | 2018 | 22 | 0.73 | Why? |
| Central Nervous System Fungal Infections | 1 | 2018 | 17 | 0.72 | Why? |
| Transfusion Medicine | 1 | 2019 | 101 | 0.68 | Why? |
| Saccharomycetales | 1 | 2018 | 118 | 0.67 | Why? |
| Skin Diseases, Bacterial | 1 | 2018 | 105 | 0.66 | Why? |
| Pathology, Clinical | 2 | 2018 | 407 | 0.61 | Why? |
| Neurosyphilis | 1 | 2015 | 17 | 0.59 | Why? |
| Syphilis Serodiagnosis | 1 | 2015 | 30 | 0.59 | Why? |
| Aspergillus fumigatus | 1 | 2018 | 239 | 0.58 | Why? |
| Treponema pallidum | 1 | 2015 | 42 | 0.57 | Why? |
| Hemostasis | 1 | 2021 | 811 | 0.55 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.54 | Why? |
| Curriculum | 2 | 2019 | 3083 | 0.54 | Why? |
| Aspergillosis | 1 | 2018 | 264 | 0.54 | Why? |
| Blood Sedimentation | 1 | 2015 | 508 | 0.51 | Why? |
| Neglected Diseases | 1 | 2018 | 381 | 0.50 | Why? |
| Blood Banks | 1 | 2019 | 535 | 0.49 | Why? |
| Antibodies, Bacterial | 1 | 2015 | 510 | 0.43 | Why? |
| Hematologic Tests | 1 | 2015 | 521 | 0.43 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.41 | Why? |
| Colitis | 1 | 2012 | 266 | 0.37 | Why? |
| Mucormycosis | 1 | 2018 | 832 | 0.36 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.33 | Why? |
| HIV Infections | 3 | 2017 | 11620 | 0.33 | Why? |
| Severe Acute Respiratory Syndrome | 8 | 2020 | 12361 | 0.28 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.28 | Why? |
| Clostridium Infections | 1 | 2012 | 595 | 0.27 | Why? |
| Education, Medical, Graduate | 1 | 2017 | 2082 | 0.25 | Why? |
| Tuberculosis, Pulmonary | 3 | 2018 | 1171 | 0.24 | Why? |
| Antitubercular Agents | 3 | 2018 | 775 | 0.24 | Why? |
| Tuberculosis, Multidrug-Resistant | 2 | 2018 | 433 | 0.23 | Why? |
| Education, Medical | 1 | 2019 | 2461 | 0.23 | Why? |
| Rifampin | 3 | 2018 | 276 | 0.22 | Why? |
| Clinical Laboratory Techniques | 5 | 2020 | 23402 | 0.22 | Why? |
| Antithrombin III | 1 | 2021 | 67 | 0.22 | Why? |
| Prothrombin | 1 | 2021 | 149 | 0.21 | Why? |
| Blood Viscosity | 1 | 2020 | 71 | 0.21 | Why? |
| Streptomycin | 1 | 2018 | 8 | 0.19 | Why? |
| Mycobacterium ulcerans | 1 | 2018 | 15 | 0.18 | Why? |
| Fungal Capsules | 1 | 2017 | 5 | 0.18 | Why? |
| Antacids | 1 | 2017 | 12 | 0.18 | Why? |
| Medical Laboratory Personnel | 1 | 2020 | 254 | 0.18 | Why? |
| Mycobacterium Infections | 1 | 2018 | 72 | 0.17 | Why? |
| Fungal Polysaccharides | 1 | 2017 | 19 | 0.17 | Why? |
| Helicobacter Infections | 2 | 2018 | 216 | 0.17 | Why? |
| Precancerous Conditions | 1 | 2018 | 108 | 0.17 | Why? |
| Pyrazinamide | 1 | 2017 | 38 | 0.17 | Why? |
| Organization and Administration | 1 | 2017 | 93 | 0.17 | Why? |
| Helicobacter pylori | 2 | 2018 | 262 | 0.17 | Why? |
| Mycobacterium avium Complex | 1 | 2017 | 61 | 0.17 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.17 | Why? |
| Clarithromycin | 1 | 2018 | 112 | 0.17 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.17 | Why? |
| Africa, Western | 1 | 2018 | 363 | 0.16 | Why? |
| Cryptococcus neoformans | 1 | 2017 | 71 | 0.16 | Why? |
| Meningitis, Cryptococcal | 1 | 2017 | 79 | 0.16 | Why? |
| Antigens, Fungal | 1 | 2017 | 106 | 0.16 | Why? |
| Drugs, Essential | 1 | 2018 | 117 | 0.16 | Why? |
| Internship and Residency | 1 | 2017 | 4987 | 0.16 | Why? |
| Blood Coagulation Tests | 1 | 2021 | 855 | 0.15 | Why? |
| Oropharynx | 3 | 2020 | 1581 | 0.15 | Why? |
| Molecular Diagnostic Techniques | 1 | 2012 | 4239 | 0.15 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| Meningoencephalitis | 1 | 2017 | 208 | 0.14 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.14 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.13 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.13 | Why? |
| Plasma Exchange | 1 | 2020 | 763 | 0.13 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.13 | Why? |
| Stomach Neoplasms | 1 | 2018 | 477 | 0.12 | Why? |
| Specimen Handling | 2 | 2020 | 6190 | 0.12 | Why? |
| Proton Pump Inhibitors | 1 | 2017 | 377 | 0.12 | Why? |
| Humans | 33 | 2021 | 930598 | 0.12 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.12 | Why? |
| Self Care | 1 | 2020 | 918 | 0.11 | Why? |
| SARS Virus | 7 | 2020 | 13021 | 0.11 | Why? |
| Schools, Medical | 1 | 2019 | 793 | 0.11 | Why? |
| Education, Medical, Continuing | 1 | 2018 | 638 | 0.11 | Why? |
| Polymerase Chain Reaction | 3 | 2018 | 6740 | 0.11 | Why? |
| DNA, Bacterial | 1 | 2015 | 835 | 0.11 | Why? |
| Bacterial Toxins | 1 | 2012 | 185 | 0.10 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.10 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.10 | Why? |
| Immunoenzyme Techniques | 1 | 2012 | 448 | 0.10 | Why? |
| Statistics as Topic | 1 | 2012 | 370 | 0.09 | Why? |
| Pulmonary Fibrosis | 1 | 2017 | 1068 | 0.08 | Why? |
| Saliva | 2 | 2020 | 4679 | 0.08 | Why? |
| Graft Rejection | 1 | 2017 | 1766 | 0.08 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.08 | Why? |
| Lung Transplantation | 1 | 2017 | 1554 | 0.08 | Why? |
| Mesocricetus | 3 | 2007 | 1847 | 0.07 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.07 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| In Situ Hybridization | 1 | 2005 | 390 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Aged | 9 | 2021 | 215776 | 0.06 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2017 | 3388 | 0.06 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.06 | Why? |
| Receptors, IgG | 1 | 2006 | 578 | 0.06 | Why? |
| Adult | 10 | 2021 | 244371 | 0.06 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Male | 12 | 2021 | 367725 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.05 | Why? |
| Metaplasia | 1 | 2018 | 43 | 0.05 | Why? |
| Disease Models, Animal | 3 | 2007 | 10998 | 0.05 | Why? |
| Chemokine CCL20 | 1 | 2018 | 47 | 0.05 | Why? |
| Students, Medical | 1 | 2019 | 4032 | 0.05 | Why? |
| Gastritis | 1 | 2018 | 66 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.05 | Why? |
| Microdialysis | 1 | 2018 | 22 | 0.05 | Why? |
| Chemokine CCL3 | 1 | 2018 | 103 | 0.05 | Why? |
| Georgia (Republic) | 1 | 2018 | 43 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.05 | Why? |
| Topoisomerase II Inhibitors | 1 | 2018 | 36 | 0.05 | Why? |
| Cricetinae | 4 | 2007 | 3344 | 0.04 | Why? |
| Flucytosine | 1 | 2017 | 12 | 0.04 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.04 | Why? |
| Feces | 1 | 2012 | 4235 | 0.04 | Why? |
| Immunohistochemistry | 1 | 2005 | 2275 | 0.04 | Why? |
| Membrane Glycoproteins | 1 | 2006 | 2273 | 0.04 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.04 | Why? |
| Interleukin-4 | 1 | 2018 | 367 | 0.04 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.04 | Why? |
| Dried Blood Spot Testing | 1 | 2020 | 383 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Female | 11 | 2021 | 380317 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Serum | 1 | 2018 | 294 | 0.04 | Why? |
| Adolescent | 5 | 2020 | 86841 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Case-Control Studies | 1 | 2015 | 17671 | 0.04 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.04 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.04 | Why? |
| Th2 Cells | 1 | 2018 | 680 | 0.04 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 502 | 0.04 | Why? |
| Tacrolimus | 1 | 2017 | 435 | 0.03 | Why? |
| Nasal Cavity | 1 | 2020 | 909 | 0.03 | Why? |
| Health Services Research | 1 | 2020 | 756 | 0.03 | Why? |
| Lung | 7 | 2018 | 31049 | 0.03 | Why? |
| Viral Envelope Proteins | 1 | 2006 | 3539 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.03 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.03 | Why? |
| Prednisone | 1 | 2017 | 652 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2018 | 1335 | 0.03 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.03 | Why? |
| Intestines | 1 | 2018 | 817 | 0.03 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.03 | Why? |
| B-Lymphocytes | 1 | 2006 | 4418 | 0.03 | Why? |
| Mexico | 1 | 2020 | 2787 | 0.03 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.02 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2006 | 8041 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Viral Vaccines | 1 | 2007 | 7560 | 0.02 | Why? |
| Inclusion Bodies | 1 | 2005 | 67 | 0.02 | Why? |
| Primates | 1 | 2007 | 584 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Cytoplasm | 1 | 2005 | 304 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Immunity, Mucosal | 1 | 2006 | 426 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| Immunotherapy | 2 | 2007 | 2421 | 0.02 | Why? |
| Ferrets | 1 | 2007 | 1201 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Macrophages, Alveolar | 1 | 2005 | 668 | 0.01 | Why? |
| Microscopy, Electron | 1 | 2003 | 830 | 0.01 | Why? |
| Cell Membrane | 1 | 2005 | 743 | 0.01 | Why? |
| Trachea | 1 | 2005 | 894 | 0.01 | Why? |
| Vaccines, Inactivated | 1 | 2007 | 1562 | 0.01 | Why? |
| Animals | 5 | 2007 | 78931 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Mice | 2 | 2007 | 21357 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2006 | 3776 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2007 | 3786 | 0.01 | Why? |
| Taiwan | 1 | 2005 | 2556 | 0.01 | Why? |
| Mice, Inbred C57BL | 1 | 2007 | 5542 | 0.01 | Why? |
| Fatal Outcome | 1 | 2005 | 3438 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Lung Diseases, Interstitial | 1 | 2006 | 1476 | 0.01 | Why? |
| Immunoglobulin A | 1 | 2006 | 3567 | 0.01 | Why? |
| Virus Replication | 2 | 2007 | 14331 | 0.01 | Why? |
| DNA, Viral | 1 | 2005 | 2521 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2003 | 2309 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Neutralization Tests | 1 | 2006 | 6698 | 0.01 | Why? |
| Immunoglobulin G | 2 | 2006 | 21571 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Antigens, Viral | 1 | 2005 | 6298 | 0.01 | Why? |
| Cell Line | 1 | 2003 | 12040 | 0.01 | Why? |
| Viral Load | 1 | 2006 | 15850 | 0.00 | Why? |
| Phylogeny | 1 | 2003 | 13341 | 0.00 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2006 | 37182 | 0.00 | Why? |
Guarner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(220)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(137)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_